Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.